Correlative studies of the breast cancer index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: A trans-aTTom study

被引：0
|
作者：
Sgroi, Dennis C. [1 ]
Treuner, Kai [2 ]
Zhang, Yi [2 ]
Piper, Tammy [3 ]
Salunga, Ranelle [2 ]
Ahmed, Ikhlaaq [4 ]
Doos, Lucy [4 ]
Thornber, Sarah [4 ]
Taylor, Karen J. [3 ]
Brachtel, Elena F. [1 ]
Pirrie, Sarah [4 ]
Schnabel, Catherine A. [2 ]
Rea, Daniel W. [4 ]
Bartlett, John M. S. [5 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Biotheranostics Inc, San Diego, CA USA
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[4] Univ Birmingham, Canc Res UK Clin Trails Unit, Birmingham, W Midlands, England
[5] Ontario Inst Canc Res, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS4-09
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
    Dennis C. Sgroi
    Kai Treuner
    Yi Zhang
    Tammy Piper
    Ranelle Salunga
    Ikhlaaq Ahmed
    Lucy Doos
    Sarah Thornber
    Karen J. Taylor
    Elena Brachtel
    Sarah Pirrie
    Catherine A. Schnabel
    Daniel Rea
    John M. S. Bartlett
    Breast Cancer Research, 24
  • [2] Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
    Sgroi, Dennis C. C.
    Treuner, Kai
    Zhang, Yi
    Piper, Tammy
    Salunga, Ranelle
    Ahmed, Ikhlaaq
    Doos, Lucy
    Thornber, Sarah
    Taylor, Karen J. J.
    Brachtel, Elena
    Pirrie, Sarah
    Schnabel, Catherine A. A.
    Rea, Daniel
    Bartlett, John M. S.
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [3] Prediction of benefit from endocrine therapy in ER plus early stage breast cancer: Correlative studies of the breast cancer index HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2 expression in the randomized Stockholm trial
    Zhang, Yi
    Schroeder, Brock E.
    Jannok, Piiha-Lotta Jerevall
    Fornander, Tommy
    Stal, Olle
    Schnabel, Catherine A.
    Sgroi, Dennis C.
    CANCER RESEARCH, 2015, 75
  • [4] Prediction of the clinical benefit of adjuvant tamoxifen therapy using Breast Cancer Index (HOXB13:IL17BR)
    Zhang, Yi
    Schroeder, Brock E.
    Jerevall, Piiha-Lotta
    Stal, Olle
    Sgroi, Dennis C.
    Erlander, Mark G.
    Schnabel, Catherine A.
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [5] Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study.
    Zhang, Yi
    Sestak, Ivana
    Cuzick, Jack M.
    Dowsett, Mitchell
    Schnabel, Catherine A.
    Sgroi, Dennis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
    Piiha-Lotta Jerevall
    Sara Brommesson
    Carina Strand
    Sofia Gruvberger-Saal
    Per Malmström
    Bo Nordenskjöld
    Sten Wingren
    Peter Söderkvist
    Mårten Fernö
    Olle Stål
    Breast Cancer Research and Treatment, 2008, 107 : 225 - 234
  • [7] Exploring the two-gene ratio in breast cancer -: independent roles for HOXB13 and IL17BR in prediction of clinical outcome
    Jerevall, Piiha-Lotta
    Brommesson, Sara
    Strand, Carina
    Gruvberger-Saal, Sofia
    Malmstrom, Per
    Nordenskjold, Bo
    Wingren, Sten
    Soderkvist, Peter
    Ferno, Marten
    Stal, Olle
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 107 (02) : 225 - 234
  • [8] Comparison of risk stratification of ER-positive, node-negative breast cancer patients by Oncotype DX versus molecular grade index and HOXB13/IL17BR ratio
    Sgroi, D.
    Hameed, O.
    Hattab, E.
    Chang, B.
    Moulis, S.
    Steffel, L.
    Salunga, R.
    Ma, X.
    Erlander, M.
    Goss, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study
    Zhang, Y.
    Sestak, I.
    Schroeder, B. E.
    Dowsett, M.
    Cuzick, J.
    Schnabel, C. A.
    Sgroi, D. C.
    CANCER RESEARCH, 2016, 76
  • [10] Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.
    Goetz, M.
    Ames, M.
    Gnant, M.
    Filpits, M.
    Jakesz, R.
    Greil, R.
    Marth, C.
    Samonigg, H.
    Suman, V
    Safgren, S.
    Kuffel, M.
    Weinshilboum, R.
    Erlander, M.
    Ma, X.-J.
    Ingle, J.
    CANCER RESEARCH, 2009, 69 (02) : 77S - 77S
1